Pcv20 Brands

Pfizer's pneumococcal conjugate vaccine franchise, originally developed by Wyeth as Prevnar (PCV7, FDA approved February 17, 2000), succeeded by Prevnar 13 (PCV13, FDA approved February 24, 2010) and Prevnar 20 (PCV20, FDA approved June 8, 2021), one of the world's best-selling vaccines with peak annual revenues exceeding $6 billion.